Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Phase 2 clinical trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) demonstrated that retatrutide produced substantial reductions in body weight up to approximately 24% over 48 weeks at the highest dose studied (12 mg once weekly) in adults with obesity alongside meaningful improvements in glycaemic control and cardiometabolic markers
This is particularly important when a headline suggests a new benefit, a newly recognized risk, or a comparison between different medicines
Reduces Pigmentation Effective for: Melasma Sun damage Dark spots 3
This decline can cause significant oxidative stress and other health problems
The future direction Clinical trials are underway to test GLP-1 RAs specifically for cognitive outcomes in cognitively healthy older adults or those with mild cognitive impairment
US$ 20.67
US$ 25.39
US$ 21.76
US$ 24.55
US$ 24.50
US$ 20.43
US$ 24.15
